中医辨证联合恩替卡韦治疗慢性乙型肝炎的临床疗效观察

目的 探讨中医辨证联合恩替卡韦治疗慢性乙型肝炎的临床疗效。方法 选取本院中医肝病门诊就诊的慢性乙型肝炎患者80例作为研究对象，随机分为观察组和对照组，每组40例。对照组患者予恩替卡韦片，观察组在对照组的基础上联合中医辨证治疗。将两组患者治疗48周后临床症状、肝功能指标、血清学转换及乙肝病毒基因的改善程度进行对比。结果 观察组在改善临床症状如腹胀、乏力、胁痛、纳差等方面均优于对照组，两组有显著差异（P<0.05）。观察组在丙氨酸氨基转移酶（ALT）复常率方面较对照组有显著治疗优势（P<0.05），尤其是在24周前效果更明显。观察组和对照组经治疗12周、24周、48周后血清学转换及乙肝病毒基因均转阴（P>0.05），结果差异无统计学意义。结论 中医辨证联合恩替卡韦治疗慢性乙型肝炎，其临床症状及肝功能生化指标改善显著，值得临床推广应用。

Clinical efficacy of TCM syndrome differentiation combined with entecavir in chronic hepatitis B patients

Objective To investigate the clinical effect of traditional Chinese medicine syndrome differentiation-based treatment combined with entecavir in the treatment of chronic hepatitis B.Methods A total of 80 outpatients with chronic hepatitis B were randomly divided into the observation group (n=40) and control group (n=40).The patients in the control group were treated with entecavir tablets. The patients in the observation group were given TCM syndrome differentiation-based treatment in addition to the treatment received by the control group. Clinical symptoms relief, improvement of liver function indexes, serological conversion and HBV-DNA negative rate were compared between the two groups after 48 weeks of treatment.Results The clinical symptoms of abdominal distension, fatigue, pain and anorexia were relieved better in observation group than in control groups. The difference was significant between the two groups (P<0.05). The observation group had significant therapeutic advantages over the ALT recurrence rate compared to the control group, especially 24 weeks ago (P<0.05). There was no statistically significant difference between the combined group and the control group after 12, 24, 48 weeks after treatment, and the HBV-DNA (both greater than 0.05) were clinically modified.Conclusion TCM syndrome differentiation-based treatment combined with entecavir had significant therapeutic advantages in the treatment of chronic hepatitis B, which could relieve clinical symptoms, improve liver function indexes, and converse serological changes and be worthy of clinical popularization.